Perspective Shifts on the Use of MS Meds During Pregnancy
Both studies — one involving the anti-CD20 monoclonal antibody ofatumumab and the other the integrin receptor antagonist natalizumab — are observational, but they provide a foundation for taking a proactive rather than reactive approach to treating pregnant women with active MS, said Riley M. Bove, MD, associate professor of neurology, University of California San Francisco.
Bove emphasized that a 'we-don't-know' approach is no longer acceptable when counseling pregnant women with active disease. As first author of the ofatumumab study — presented on May 29 at Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting— she followed up with a lecture the next day, explaining that evidence is now available to guide treatment decisions.
Relevant Data
While significant knowledge gaps remain about the relative risks of DMTs to fetal development and pregnancy outcomes, it is well established that women with active disease 'will be harmed if we do not help,' Bove said.
She and others now believe that the available data, even if observational, are relevant and useful in guiding decisions that affect both maternal and fetal health.
The new data on ofatumumab and natalizumab offer a clear example.
In an ongoing registry, ofatumumab exposure has been documented in 669 pregnancies.
Of these, 221 were reported prior to 2023, allowing for assessment of both short- and long-term outcomes. In most cases (87%), exposure occurred during the first trimester.
Adverse outcomes were reported, including spontaneous abortions in 12.6% of cases, preterm births in 9.6%, and minor congenital malformations in two infants (< 1%).
However, these rates are 'in line with the background rates observed in the general population,' Bove noted. She emphasized that such data are important when weighing treatment decisions against the known risks of active disease, which can lead to irreversible brain injury in the mother.
The natalizumab data, presented as a late-breaking abstract at CMSC on May 30, reflected 16 years of experience at a single center. Tracking began in 2008, when two pregnancies were identified in women already receiving natalizumab.
Through 2024, no increased risk for adverse pregnancy outcomes was observed, while natalizumab treatment was associated with meaningful improvements in MS disease control.
A total of 58 pregnancies in 43 women have been tracked at the Rocky Mountain MS Clinic in Salt Lake City, according to Katrina Bawden, FNP-C, a nurse practitioner who has been involved since the registry began.
Reevaluating Natalizumab
She noted that outcomes were analyzed in women who discontinued natalizumab after learning they were pregnant as well as those who continued treatment into the third trimester.
Among the 38 pregnancies in which natalizumab was stopped, 13 women experienced clinical relapses, and four others showed new lesions on MRI. In contrast, among the 20 pregnancies where treatment was continued, there were no relapses and no MRI evidence of disease activity.
Pregnancy complications were observed, including one fetal malformation and 10 miscarriages, but Bawden noted that these figures — like those in the ofatumumab registry — are consistent with background rates.
'Of the three fetal deaths, all occurred in those who discontinued natalizumab,' she said. She noted that all 10 of the women who miscarried had healthy term full term deliveries in a subsequent pregnancy while remaining on natalizumab.
Compared to the start of the tracking period, Bawden said the data have prompted clinicians at her clinic to reevaluate the benefit-risk balance of using natalizumab during pregnancy.
'Women at the Rocky Mountain MS Clinic who become pregnant while treated with natalizumab, using shared decision-making, are now given the option of continuing natalizumab every 8 weeks throughout pregnancy with the last dose scheduled at 34 weeks' gestation,' Bawden said.
'Illogical Guidance'
Caring for pregnant women with MS is a complex challenge, given the incomplete information available. However, Bove — co-author of a 2024 paper on practical considerations for weighing the risks and benefits of DMT use during pregnancy — said that strictly following drug labeling is not helpful in guiding clinical decisions.
She noted that current recommendations are inconsistent across drug classes, vary between the FDA and the European Medicines Agency, and often fail to reflect the latest science — resulting in guidance that is ultimately 'illogical.'
Moreover, labeling continues to evolve, and pregnancy-related use of DMTs remains a dynamic area, with new data — such as the recent studies presented at CMSC — shaping clinical strategies.
Bove emphasized that it is the clinician's responsibility to stay informed as the evidence develops, in order to support shared decision-making. This includes staying up to date on when to treat active disease during pregnancy, when to restart therapy if it was paused, and how to weigh the benefit-risk profile of DMTs for women who choose to breastfeed.
When making MS treatment decisions during pregnancy, the adage 'first, do no harm' has traditionally focused on fetal risk. But Bove pointed out that withholding treatment may, in many cases, pose greater harm to the mother, underscoring the need for a balanced discussion that considers risks to both mother and fetus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
Trump Administration Violated Order on U.C.L.A. Grant Terminations, Judge Says
A federal judge in California ordered the National Science Foundation to reinstate millions of dollars in grants awarded to the University of California, Los Angeles, finding that the agency had tried to circumvent a ruling in June requiring restoration of the funds. In a pointed order on Tuesday evening, Judge Rita F. Lin wrote that the Trump administration had misleadingly framed its latest attempt to cancel the grants as suspensions. 'N.S.F. claims that it could simply turn around the day after the preliminary injunction' and freeze 'funding on every grant that had been ordered reinstated, so long as that action was labeled as a 'suspension' rather than a 'termination,'' she wrote. 'This is not a reasonable interpretation.' Judge Lin, a Biden appointee, noted in the order that the University of California system had lost around $324 million in grant funding earlier this year as the Trump administration began culling science funding for projects it considered out of step with the president's agenda. In the previous ruling in June, Judge Lin informed the Trump administration that it could issue cancellations of individual grants for coherent reasons, but not blanket terminations. But beginning on July 30, the administration sent out a round of letters announcing what Judge Lin described as 'en masse, form letter funding cuts,' targeting U.C.L.A. specifically, freezing more than $300 million in research funds. That sum appeared to include around $81 million in funding awarded by the N.S.F. The judge said that letters on the cuts echoed familiar grievances about the university's handling of diversity in admissions practices, alleged antisemitism on campus and policies surrounding transgender athletes — the same grounds on which the administration has tried to extract enormous settlements from Harvard and other universities in recent weeks. Judge Lin said that the Trump administration's freezing of university grants appeared designed more to suspend research the Trump administration has associated with liberal causes than to sincerely address concerns about racism or antisemitism. In a related case focused on grants from the National Institutes of Health, a federal judge in Massachusetts described the cancellations of those grants as discriminatory toward racial and sexual minorities and driven by animus toward vulnerable groups. He similarly ordered that funding restored in an impassioned ruling from the bench in June. In Judge Lin's ruling, she directed the government to return next Tuesday to update the court on its progress in complying with the order.
Yahoo
an hour ago
- Yahoo
‘Alien' Has Always Feared AI and Big Corporations. That's More Relevant Than Ever
The new FX series 'Alien: Earth' traffics in familiar themes about greed, oligarchy and mysterious robots that tie into what's going on in the real world The 'Alien' movies vary widely in quality — there arguably hasn't been a truly satisfying one since the first two in 1979 and 1986 — but a key thread has endured across the 46 years: However scary the xenomorphs are, 'Alien' has always feared AI and the greed of faceless corporations. And in that respect, its time has come. The latest entry in the franchise, 'Alien: Earth,' which premieres on Tuesday, certainly exhibits those political undercurrents while bringing the threat home, both in the location and the shift from theaters to FX and Hulu, where only your neighbors can hear you scream. More from TheWrap Jimmy Fallon's Greg Gutfeld Interview Scores Biggest 'Tonight Show' Audience Since 2023 | Exclusive 'Wednesday' Season 2 Debuts to 50 Million Views in Just 5 Days on Netflix 'Alien' Has Always Feared AI and Big Corporations. That's More Relevant Than Ever Alex Ross Perry's 'Videoheaven' Charts the Rise and Fall of Video Stores, I Was There | Essay Granted, nobody comes to an 'Alien'-branded project — a franchise with one foot firmly planted in sci-fi and horror — for a lecture about the perils of unfettered capitalism. Still, the underlying apprehensions feel even timelier now, from the AI threat to the notion of corporations supplanting governments. 'Alien: Earth' lands at a moment of heightened unease about income inequality and the growing political clout wielded by billionaires like Elon Musk, Mark Zuckerberg and Jeff Bezos — moguls who have become household names. Their companies, meanwhile, keep growing, with trillion-dollar valuations — which would have sounded like the stuff of science fiction a few decades ago — now a reality, with Microsoft, Apple, Amazon and Google among those cracking that barrier. 'The Trillion Dollar Stock Club Is Bigger — and Richer— Than Ever,' blared Barron's headline closing 2024. Despite healthy profits, those same companies are also embracing AI in a way that both ignores potential unintended consequences and threatens the careers of its own employees. Several have explicitly stated as much, with Amazon CEO Andy Jassey issuing a memo in June spelling out that the technology will 'reduce our total corporate workforce as we get efficiency gains from using AI extensively across the company.' The eight-episode series takes the real-world drift toward corporate oligarchy to its dystopian extreme, with Earth governed by five massive corporations, which, as usual, exhibit few compunctions about sacrificing human life to advance their objectives and enhance their profits. In the broad strokes, though, this latest addition to the mythology — as conceived by showrunner Noah Hawley, who previously translated 'Fargo' to TV — very much contains the same core of distrusting those in charge, along with some new wrinkles that work more fitfully. The end game of those corporate objectives as usual remains murky, but again involves using synthetic androids — whose actions and motivations prove suspect — and seeking the means to capitalize on the alien creatures. Naturally, that requires the customary hubris about attempting to cash in on something so uncontrollable, unpredictable and dangerous. By adding a human face, in the form of a young technocrat (Samuel Blenkin) running a company appropriately named Prodigy Corp., 'Alien: Earth' does endeavor to make the story more contemporary. The self-proclaimed 'boy genius' feels like a composite inspired by any number of CEOs, which says something about this plutocratic moment given that the character would have seemed exaggerated or cartoonish before the modern tech explosion. As Hawley said during a pre-launch press conference, 'If I had done the 1970s version of capitalism it wouldn't have felt right for the world we live in today,' adding that humanity is 'trapped between the AI future and the monsters of the past.' The shock of the first 'Alien' — beyond wedding a haunted house to striking monster biology and set design — hinged in part on the cavalier attitude 'the company' harbored toward the lives of the crew. What they intended to do with the xenomorph was ill defined — something about the bio-weapons division — but the key point was treating the survival of those manning the ship as a secondary concern. That aspect became even more pronounced in the brilliant sequel 'Aliens,' directed by James Cameron, which features Paul Reiser as Burke, a mid-level manager, and the kind of corporate suck-up everyone has encountered. Burke gradually reveals who he is, balking at eradicating the aliens because a space installation has a 'substantial dollar value,' before seeking to curry favor from his superiors by allowing Ripley (Sigourney Weaver) and a young child to be 'impregnated' by the monster in order to bring specimens home. As Ripley says whens he exposes the plot, 'You know, Burke, I don't know which species is worse. You don't see them fucking each other over for a goddamn percentage.' Their shortcomings aside, the subsequent films, up to last year's 'Alien: Romulus,' have continued playing with these themes. Even after it was given a name, the company, Weyland-Yutani, cares more about the research and development possibilities in that enticing alien DNA than preserving the humans in its employ. Of course, there's some irony in that, since 'Alien' has itself become a title with a 'substantial dollar value,' spanning nine movies (including two crossovers with the 'Predator' franchise) totaling almost $2 billion in global box office. In an interview last year, original director Ridley Scott conceded the third and fourth films 'ran that firmly into the ground,' while more generously appraising the subsequent sequels, having directed two of them. In later episodes, 'Alien: Earth' pointedly addresses some of the issues the franchise has contemplated, with a character discussing the irony of smart people who are 'too stupid to realize you don't bring parasites home with you.' There's a possible lesson there regarding AI, where the lure of its potential might be blinding us to its dangers, and massive real-world companies appear either oblivious — or worse, indifferent — to the societal harm that it might do. That's evident in the commentary from the likes of Meta and OpenAI, who are pouring billions of dollars in an AI arms race against each other and China. Even if the robots don't murder us, as envisioned in the sci-fi version of these scenarios, they appear more tangibly destined to replace us by killing off a lot of our jobs. The employees in 'Alien: Earth' also recognize who's calling the shots, with one acknowledging that everything being done and the risks they're facing are 'always about power,' which includes exploring space to serve the company's ends. 'Alien' notably premiered at the close of the 1970s, a decade seen as a golden age for paranoid conspiracy thrillers — including those that reflected the callousness of corporate greed, like 'The China Syndrome' and 'Coma.' In that sense, having five corporations run things, like the American Mafia's five families, hardly feels like an accident. Because in 'Alien,' then and now, 'the company' rules the world, and the rest of us just try to hang on working for them. 'Alien: Earth' premieres Aug. 12 on FX and Hulu. The post 'Alien' Has Always Feared AI and Big Corporations. That's More Relevant Than Ever appeared first on TheWrap.
CBS News
an hour ago
- CBS News
With vaccination rates falling, Chicago area health officials urge measles shots for kids
The number of students who have not been vaccinated for measles in suburban Cook County has doubled in the past decade. With school starting next week for thousands of students, health officials are urging parents to get their kids vaccinated. Measles was believed to have been eliminated in the United States in 2000. But cases have steadily increased in recent years. Right now, the U.S. is seeing the highest number of measles cases in more than 30 years — with more than 1,300 across the country. A total of 10 have been reported in Cook County. Centers for Disease Control and Prevention data show childhood vaccination rates have fallen again in the U.S. A total of 92.5% of kindergartners got the measles-mumps-rubella shot, down yet again from the previous year. Before the COVID pandemic, 95% of kindergartners nationwide got the shot — the level necessary to maintain herd immunity. "Our job is to educate, sort of combat some of the misinformation that's spread out there on social media — just to make sure they understand what's medically relevant, irrelevant, and to know the facts," said pediatrician Dr. Andrea Jakinovich. Parents can now look up measles vaccination rates school-by-school across the state and use the new Illinois Department of Public Health measles simulator to determine the risk of a child being exposed if a case is introduced at school. "Vaccines have been studied for years and years and years," Jakinovich said. "We want parents to understand that they're safe, that they're effective, and the bottom line is just really to prevent disease." Two doses of the MMR vaccine are recommended in children, and they typically protect people for life. On Wednesday morning, health, religious, and community leaders will deliver what they call a united effort to encourage people to get vaccinated against measles. The Illinois Department of Public Health also plans on rolling out a vaccination awareness campaign Wednesday.
